OPTIMA HEALTH PLAN

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>1-800-750-9692</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

Drug Requested: (check applicable drug below)				
	Xe	enazine® (tetrabenazine)	□ tetrabenazine	
D	RU	G INFORMATION: Complete information	below or authorization will be delayed if incomplete.	
Dr	ug l	Name/Form:		
Drug Strength:			Dosing Schedule:	
Length of Therapy:			ICD Code, if applicable:	
Di	agn	osis:		
CLINICAL CRITERIA: Check below <u>ALL</u> that apply. <u>ALL</u> criteria <u>must</u> be met for approval. <u>ALL</u> documentation including labs or chart notes (if required) <u>must</u> be submitted or request will be denied.				
□ For Xenazine® approval:				
	☐ Medication is prescribed by or in consultation with a Neurologist; AND			
	□ Patient MUST have a diagnosis of chorea associated with Huntington's Disease (chart notes must document diagnostic criteria and symptoms); AND			
		Patient must have trial and failure of at least 30 c therapy failure)	lays of tetrabenazine (chart notes must document	
	Fo	or tetrabenazine approval:		
		Medication is prescribed by or in consultation wi	th a Neurologist; AND	
		Patient MUST have a diagnosis with chorea asso document diagnostic criteria and symptoms)	ciated with Huntington's Disease (chart notes must	
Medication being provided by a Specialty Pharmacy - PropriumRx				
		(continued on next page; signature pag	ge must be attached to this request form)	

(Signature page **MUST** be included with request form)

Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.

Date:

^{*}Approved by Pharmacy and Therapeutics Committee: 7/19/18 REVISED/UPDATED: 9/28/2018; (Reformatted) 7/9/2019;